This company develops and provides advanced robotic systems designed for complex biological research and laboratory automation. Their platforms enable high-throughput screening and precise manipulation of biological samples, accelerating discovery in the life sciences. They offer integrated hardware and software solutions to streamline demanding experimental workflows.
Funding
Funding not disclosed
Founders
Product
Problem
Effective targeted delivery of RNA therapies remains a challenge due to difficulties in directing therapeutics to specific cells or tissues. Traditional diagnostic methods for infectious diseases and cancer can be slow, costly, and lack the modularity for rapid adaptation to new pathogens or biomarkers.
Solution
Atom Bioworks is developing a DNA-based material platform coupled with AI-enabled design software to address these challenges. Their technology facilitates the creation of high-affinity binding materials for targeted drug delivery, specifically aptamer-conjugated lipid nanoparticles (aptLNPs) for nucleic acid delivery. Additionally, they offer a DNA-Net disease detection platform that enables modular development of rapid diagnostics for infectious diseases and cancer through pathogen surface pattern matching. The platform aims to reduce development time and costs associated with creating effective therapeutics and diagnostics.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted drug delivery systems and rapid diagnostic tools.
Features
- AI-enabled DNA design software for creating custom nanomaterials.
- aptLNP technology for targeted delivery of nucleic acids.
- DNA-Net platform for modular development of rapid diagnostics.
- High-affinity binding materials for improved therapeutic targeting.
- Nanometer-scale biomaterial design and manufacturing capabilities.